Form 8-K - Current report:
SEC Accession No. 0001193125-26-160355
Filing Date
2026-04-17
Accepted
2026-04-17 08:06:31
Documents
17
Period of Report
2026-04-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d587027d8k.htm   iXBRL 8-K 44900
2 EX-1.1 d587027dex11.htm EX-1.1 208380
3 EX-5.1 d587027dex51.htm EX-5.1 8533
4 EX-99.1 d587027dex991.htm EX-99.1 9261
8 GRAPHIC g587027dsp1.jpg GRAPHIC 7814
9 GRAPHIC g587027g0416081742180.jpg GRAPHIC 2692
10 GRAPHIC g587027g0417033330585.jpg GRAPHIC 6465
  Complete submission text file 0001193125-26-160355.txt   479218

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA trvi-20260416.xsd EX-101.SCH 3207
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20260416_lab.xml EX-101.LAB 17992
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20260416_pre.xml EX-101.PRE 11279
20 EXTRACTED XBRL INSTANCE DOCUMENT d587027d8k_htm.xml XML 3639
Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 26869468
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)